Low-dose Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) as an Alternative Therapy for Ovarian Cancer in an Octogenarian Patient

被引:0
作者
Giger-Pabst, Urs [1 ]
Solass, Wiebke [3 ]
Buerkle, Bernd [2 ]
Reymond, Marc-Andre [1 ]
Tempfer, Clemens B. [2 ]
机构
[1] Ruhr Univ Bochum, Dept Surg, Bochum, Germany
[2] Ruhr Univ Bochum, Dept Obstet & Gynecol, Bochum, Germany
[3] Hannover Med Sch, Inst Pathol, Hannover, Germany
关键词
Ovarian cancer; quality of life; antineoplastic agents; adverse effects; intraperitoneal chemotherapy; peritoneal carcinomatosis; octogenarian; high pressure; QUALITY-OF-LIFE; PERITONEAL CARCINOMATOSIS; FEASIBILITY; CISPLATIN; WOMEN;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Octogenarians with ovarian cancer limited to the abdomen may not be willing or able to undergo systemic chemotherapy. Low-dose pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin is a form of intra-abdominal chemotherapy which can be applied repeatedly and potentially prevents from the systemic side-effects of chemotherapy. Case Report: We present the case of an 84-year-old woman with laparoscopically and histologically confirmed ovarian cancer who refused to undergo systemic chemotherapy. She was treated with eight courses q 28-104 days of low-dose PIPAC with cisplatin at 7.5 mg/m(2) and doxorubicin at 1.5 mg/m(2) at 12 mmHg and 37 degrees C for 30 min. Objective tumor response was noted, defined as tumor regression on histology, and stable disease noted by peritoneal carcinomatosis index on repeated video-laparoscopy and abdominal computed tomographic scan. The treatment was well-tolerated with no Common Terminology Criteria for Adverse Events (CTCAE) CTCAE >2. With a follow-up of 15 months, the patient is alive and clinically stable. The quality of life measured by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 demonstrated improvement over 5-6 months (global physical score, global health score, global quality of live) without cumulative increase of gastrointestinal toxicity. Conclusion: Low-dose PIPAC is a new form of intra peritoneal chemotherapy which may be applied repeatedly in octogenarian patients. PIPAC may be an alternative and well-tolerated treatment for selected octogenarian patients with ovarian cancer limited to the abdomen who cannot be treated with systemic chemotherapy.
引用
收藏
页码:2309 / 2314
页数:6
相关论文
共 50 条
  • [21] Safety and preliminary efficacy of electrostatic precipitation during pressurized intraperitoneal aerosol chemotherapy (PIPAC) for unresectable carcinomatosis
    Willaert, W.
    Van de Sande, L.
    Van Daele, E.
    Van De Putte, D.
    Van Nieuwenhove, Y.
    Pattyn, P.
    Ceelen, W.
    EJSO, 2019, 45 (12): : 2302 - 2309
  • [22] Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal carcinomatosis: systematic review of clinical and experimental evidence with special emphasis on ovarian cancer
    Clemens Tempfer
    Urs Giger-Pabst
    Ziad Hilal
    Askin Dogan
    Günther A. Rezniczek
    Archives of Gynecology and Obstetrics, 2018, 298 : 243 - 257
  • [23] First Indian Study on Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Procedure for Advanced Peritoneal Carcinomatosis Secondary to Epithelial Ovarian Cancer
    Somashekhar S.P.
    Rajagopal A.K.
    Zaveri S.S.
    Chandrashekhar R.K.
    Rauthan A.
    Rakshit S.H.
    Indian Journal of Gynecologic Oncology, 2018, 16 (2)
  • [24] Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal carcinomatosis: systematic review of clinical and experimental evidence with special emphasis on ovarian cancer
    Tempfer, Clemens
    Giger-Pabst, Urs
    Hilal, Ziad
    Dogan, Askin
    Rezniczek, Guenther A.
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2018, 298 (02) : 243 - 257
  • [25] Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) as an outpatient procedure
    Graversen, Martin
    Lundell, Lars
    Fristrup, Claus
    Pfeiffer, Per
    Mortensen, Michael B.
    PLEURA AND PERITONEUM, 2018, 3 (04)
  • [26] Exploring the Spatial Drug Distribution Pattern of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC)
    Veria Khosrawipour
    Tanja Khosrawipour
    David Diaz-Carballo
    Eckart Förster
    Jürgen Zieren
    Urs Giger-Pabst
    Annals of Surgical Oncology, 2016, 23 : 1220 - 1224
  • [27] Reasons for stopping Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC): A retrospective study to improve future patient selection
    Ezanno, Anne-Cecile
    Malgras, Brice
    Conan, Pierre-Louis
    Aime, Adeline
    Fawaz, Jade
    Picchi, Hugo
    Doat, Solene
    Pocard, Marc
    PLOS ONE, 2023, 18 (11):
  • [28] Perioperative safety of intraperitoneal aerosol chemotherapy. Analysis of our first 111 pressurized intraperitoneal aerosol chemotherapy (PIPAC) procedures
    Jansen-Winkeln, B.
    Thieme, R.
    Haase, L.
    Niebisch, S.
    Pommer, C.
    Lyros, O.
    Zimmer, J.
    Lordick, F.
    Remane, Y.
    Frontini, R.
    Gockel, I.
    CHIRURG, 2019, 90 (02): : 137 - 145
  • [29] Peritoneal metastasis from pancreatic cancer treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC)
    Graversen, Martin
    Detlefsen, Sonke
    Bjerregaard, Jon Kroll
    Pfeiffer, Per
    Mortensen, Michael Bau
    CLINICAL & EXPERIMENTAL METASTASIS, 2017, 34 (05) : 309 - 314
  • [30] Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for unresectable peritoneal metastasis from gastric cancer
    Alyami, Mohammad
    Bonnot, Pierre-Emmanuel
    Mercier, Frederic
    Laplace, Nathalie
    Villeneuve, Laurent
    Passot, Guillaume
    Bakrin, Naoual
    Kepenekian, Vahan
    Glehen, Olivier
    EJSO, 2021, 47 (01): : 123 - 127